JMERC
Owner
Janbazan Medical and Engineering Research Center (JMERC) is the owner of IJWPH.
0.3
Cite Score
SJR: 0.114 / SNIP: 0.090
Volume 15, Issue 4 (2023)
Iran J War Public Health 2023, 15(4): 1022-1028 |
Back to browse issues page
Article Type:
Subject:
History
Received: 2024/02/1 | Accepted: 2024/03/4 | Published: 2023/04/15
Received: 2024/02/1 | Accepted: 2024/03/4 | Published: 2023/04/15
How to cite this article
Muna Abdulridha Al-Barqaawi, Zainab Tawfeeq Al_Joubouri, Suad Lateef Ibrahim. The connection between hospitalised patients' COVID-19 and thyroid dysfunction. Iran J War Public Health 2023; 15 (4) :1022-1028
URL: http://ijwph.ir/article-1-1437-en.html
URL: http://ijwph.ir/article-1-1437-en.html
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Rights and permissions
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
1- Department of Biochemistry, Faculty of Medicine, University of Kufa, Iraq.
2- Department of Pharmacology and Toxicology, Faculty of Pharmacy, University of Kufa, Iraq.
3- Department of Clinical Laboratory Sciences, Faculty of Pharmacy, University of Kufa, Iraq.
2- Department of Pharmacology and Toxicology, Faculty of Pharmacy, University of Kufa, Iraq.
3- Department of Clinical Laboratory Sciences, Faculty of Pharmacy, University of Kufa, Iraq.
Abstract (26 Views)
Aims: COVID-19 has been around for nearly 3 years now. Although vaccines have been developed it continue to present problems to the health sector. With many studies conducted so far, it is still not fully understood with room for better understanding of its effects on the body generally and thyroid function more specifically. In order to ascertain if COVID-19 infection was linked to thyroid function abnormalities, the current study assessed thyroid function in all hospitalised patients who had been diagnosed with the virus.
Methods: A sample of blood was collected during hospitalization. Serum was used for determination of thyroid-stimulating hormone (TSH). TSH was assayed on automated integrated clinical chemistry and immunoassay analyzer.
Results: COVID-19 patients' mean (SD) age was 48.42 years (9.50 years), while COVID-19-negative patients' mean (SD) age was 37.72 years (12.88 years). females were being the majority of populations in the COVID-19 group (60%), while male was prevalence between the control group (the COVID-19–negative group), (62%). The comparison between COVID-19 group and COVID-19–negative group indicated a significant difference in age and (BMI) (P < .0001) and (P < .01) difference in gender. Systolic and diastolic blood pressure significantly (p< 0.001, p<0.001 respectively) different between group with COVID-19 compared with COVID-19–negative group. Laboratory data showed a significant difference between patients COVID-19 compared with COVID-19–negative group in FBS (P< .0001), HbA1C (P< .0001), ALT (P< .0001), and AST (P< .01). Also, analysis indicted a significant (p<0.001) difference between COVID-19 patients compared with COVID-19–negative group in the level of TSH. Also, ROC analysis indicated that TSH, IL-6 and d-dimer, were good prognosticator for disease negative outcome, TSH (AUC = 0.96; 95% CI: 0.93–0.99, p<0.001), IL-6 (AUC = 0.96, 95% CI: 0.91–1.00, p<0.001) and d-dimer (AUC = 0.72 95% CI: 0.63-0.82, p<0.001 respectively). Spearman correlation plot between TSH and biomarkers such as IL-6 and d-dimer pointed out that a strong significant (r = - 0.97, p<0.001) and (r = - 0.66, p<0.001) correlations between IL-6 and d-dimer were inversely correlated to TSH.
Conclusions: In most individuals admitted to the hospital with a COVID-19 infection, thyroid impairment was evident.Furthermore, in COVID-19-infected individuals, low TSH levels were a reliable indicator of poor prognosis. TSH may be lowered in COVID-19 individuals in part due to IL-6. Thus, the current study lends credence to the notion that anti-IL-6 medication targeting the cytokine storm caused by COVID-19 may be a viable therapeutic strategy for improving COVID-19 patient outcomes in conjunction with supportive care techniques.
Methods: A sample of blood was collected during hospitalization. Serum was used for determination of thyroid-stimulating hormone (TSH). TSH was assayed on automated integrated clinical chemistry and immunoassay analyzer.
Results: COVID-19 patients' mean (SD) age was 48.42 years (9.50 years), while COVID-19-negative patients' mean (SD) age was 37.72 years (12.88 years). females were being the majority of populations in the COVID-19 group (60%), while male was prevalence between the control group (the COVID-19–negative group), (62%). The comparison between COVID-19 group and COVID-19–negative group indicated a significant difference in age and (BMI) (P < .0001) and (P < .01) difference in gender. Systolic and diastolic blood pressure significantly (p< 0.001, p<0.001 respectively) different between group with COVID-19 compared with COVID-19–negative group. Laboratory data showed a significant difference between patients COVID-19 compared with COVID-19–negative group in FBS (P< .0001), HbA1C (P< .0001), ALT (P< .0001), and AST (P< .01). Also, analysis indicted a significant (p<0.001) difference between COVID-19 patients compared with COVID-19–negative group in the level of TSH. Also, ROC analysis indicated that TSH, IL-6 and d-dimer, were good prognosticator for disease negative outcome, TSH (AUC = 0.96; 95% CI: 0.93–0.99, p<0.001), IL-6 (AUC = 0.96, 95% CI: 0.91–1.00, p<0.001) and d-dimer (AUC = 0.72 95% CI: 0.63-0.82, p<0.001 respectively). Spearman correlation plot between TSH and biomarkers such as IL-6 and d-dimer pointed out that a strong significant (r = - 0.97, p<0.001) and (r = - 0.66, p<0.001) correlations between IL-6 and d-dimer were inversely correlated to TSH.
Conclusions: In most individuals admitted to the hospital with a COVID-19 infection, thyroid impairment was evident.Furthermore, in COVID-19-infected individuals, low TSH levels were a reliable indicator of poor prognosis. TSH may be lowered in COVID-19 individuals in part due to IL-6. Thus, the current study lends credence to the notion that anti-IL-6 medication targeting the cytokine storm caused by COVID-19 may be a viable therapeutic strategy for improving COVID-19 patient outcomes in conjunction with supportive care techniques.